Scienmag
MARCH 25, 2021
Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases Credit: Insilico Medicine Thursday, 25th of March 2021 (5:00AM EST) — Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for […].
Scienmag
NOVEMBER 9, 2020
Credit: Insilico Tuesday, November 10, 2020 (9AM Beijing) – Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica N.V.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
DECEMBER 23, 2020
The Phase 3 clinical trial showed that the drug, called CC-486, significantly improved survival in older patients, over the age of 55, with AML A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement […].
Scienmag
SEPTEMBER 4, 2020
Anticholinergic medications are used for many conditions but might also accelerate cognitive decline, especially in older persons with biological or genetic risk factors A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies (..)
Scienmag
JANUARY 5, 2021
– A novel form of a drug used to treat osteoporosis that comes with the potential for fewer side effects may provide a new option for patients. Credit: Chris Adam/Purdue University WEST LAFAYETTE, Ind. The work is supported by the National Institutes of Health and is published in Biophysical Journal.
Scienmag
FEBRUARY 1, 2021
Credit: UVA Health Scientists have identified a group of drugs that may help stop a leading cause of vision loss after making an unexpected discovery that overturns a fundamental belief about DNA. The drugs, known as Nucleoside Reverse Transcriptase Inhibitors, or NRTIs, are commonly used to treat HIV.
Scienmag
OCTOBER 21, 2020
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.
Expert insights. Personalized for you.
76 
Let's personalize your content